Untitled

HealthTrust presents…“Present Use & Future Directions of Bispecific Molecules in Relapsed or Refractory Multiple Myeloma”

Multiple myeloma is a malignant neoplasm of plasma cells in the blood that accumulate in the bone marrow, leading to blood dyscrasias, bone damage, infections, and renal damage. Due to the incurable nature of the malignancy, patients may undergo several lines of treatment. Multiple myeloma remains incurable, therefore, the development of additional options for relapsed or refractory disease is vital. Approved therapies have shown success targeting B-cell maturation antigen (BCMA); however, additional targets are being explored in clinical trials. Due to the evolving nature of oncology, pharmacists are consistently introduced to new therapies and thus should be familiar with those in development. This session will focus on current FDA-approved bispecific molecules, differentiating between bispecific antibodies and bispecific T-cell engagers, toxicities associated with these therapies, and current NCCN guideline recommendations. Ongoing clinical trials and advances in bispecific research will also be provided to highlight the evolving future of these agents.

Learning Objectives for Pharmacists & Nurses  |  At the end of this session, participants should be able to:

1. Recall the current landscape of bispecific molecule treatment of relapsed or refractory multiple myeloma
2. Identify the differences between current FDA approved bispecific antibodies and bispecific T-cell engagers
3. Recognize treatment strategies currently being utilized in bispecific molecule clinical trials

Presenter:

Brielle Stawicki, PharmD  |  PGY-1 Resident  |  Atlantic Health System

Target Audience: Pharmacists, Nurses &  Physicians

CE Credit: Approved for Nurses, pending for Pharmacists

This program is pending approval for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of this program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this activity is pending. The activity is pending approval for Pharmacists & approved for Nurses for 1 hour (.1 CEUs) of continuing education credit for those who attend the webinar and complete the online evaluation. Pfiedler Education is a division of AORN, provider approved by the California Board of Registered Nursing, Provider Number CEP13019, for 1 contact hour. 1.0 contact hours approved for Nurses.

Note about CE credit: If you plan to obtain credit for a live session, stay until the end of the presentation to receive the verification code you will need to obtain the continuing education credit. CE credit is individual. No group credit is available. Each person must register for a webinar and attend the webinar in its entirety in order to receive an email after the event with instructions on how to apply for continuing education credit. Attendees should not share the code or forward the email to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.